With over 35 nationalities and a range of backgrounds represented in our Benevolent team, we aim to build an inclusive environment where our people can bring their authentic selves to work, be respected for who they are and the exceptional work they do. We welcome and actively encourage applications from all sections of society and are committed to offering equal employment opportunities regardless of sex, race, religion or belief, ethnic or national origin, marital, domestic or civil partnership status, sexual orientation, gender identity, parental status, disability, age, citizenship, or any other basis. We see our diversity as an asset as we tackle challenging problems that bridge the gap between drug discovery and technology.
We are looking for an experienced Senior Chemoinformatics Data Scientist with demonstrable expertise in drug discovery project work to apply state of the art methods to positively impact the advancement of our small molecule Drug Discovery programmes.
You will contribute to a high performing cross-functional team that seek to apply their knowledge to a diverse range of programmes from Target Identification through to Hit ID, Hit Expansion and Lead Optimisation.
We’ve assembled an exceptionally diverse, talented and spirited team who sincerely enjoy coming to work every single day to bring their ideas and a real passion for new technology and medical discovery. You will work alongside recognised thought leaders at the cross-section of Machine Learning, Chemistry data and Drug Discovery.
You will apply your skills and experience to advance the drug discovery programmes in our portfolio. This includes devising computational solutions to project-specific challenges and applying new and existing technologies to support the needs of our wider portfolio.
We share a passion for being part of a mission that matters, and we are always looking for curious and collaborative people who share our values and want to be part of our journey. If that sounds like a fit for you, hit the apply button and join us.
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Our team will only contact you from the domain @benevolent.ai. If you receive a suspicious contact request, please email email@example.com. Thank you.